| 2024-09-17 | +4.08 % |
|
| 2024-09-16 | +1.3 % |
- Moderna (MRNA) stock rose by 1.3% due to positive investor sentiment linked to the Federal Reserve's anticipated rate cuts and the overall market outlook, which suggests favorable conditions for investments in technology and healthcare sectors, including biotech.
- Moderna (MRNA) stock experienced a 1.3% increase, likely influenced by investor optimism surrounding the general positive momentum in the biotechnology sector, particularly following JPMorgan's upgrade of BioNTech (BNTX) amid encouraging data from its oncology pipeline, which parallels themes of diversification and growth that also apply to Moderna.
- Moderna (MRNA) stock increased by 1.3% due to rising COVID-19 levels and the approach of flu season, which is driving demand for updated respiratory virus vaccines, including those provided by Moderna.
- Moderna (MRNA) stock rose by 1.3% amid rising Covid-19 levels in the United States and an approaching respiratory disease season, as the demand for updated Covid-19 vaccines from Moderna and Pfizer increases to help combat the circulating variants.
The stock's increase is likely due to the anticipation of higher vaccine uptake as public health officials stress the importance of vaccination to mitigate the impact of upcoming respiratory illnesses, including Covid-19, flu, and RSV.
|
| 2024-09-13 | -2.01 % |
|
| 2024-09-12 | -12.36 % |
|
| 2024-09-11 | +0.29 % |
|
| 2024-09-10 | +3.49 % |
|
| 2024-09-09 | +5.1 % |
|
| 2024-09-06 | -0.75 % |
|
| 2024-09-05 | +1.31 % |
- Moderna (MRNA) stock rose by 1.31% following news of a class action lawsuit against the company regarding allegations that it misled investors about the efficacy of its RSV vaccine, mRNA-1345, which may indicate optimism about its future or resolution of related uncertainties.
The stock increase might be attributed to investor sentiment reacting positively to the developments or recent performance indicators, despite the underlying legal issues.
- Moderna (MRNA) stock rose 1.31% due to the FDA's approval of updated vaccines amid a surge in COVID-19 infections, coinciding with the end of the federal Bridge Access program, which will require millions of uninsured Americans to pay out-of-pocket for vaccines.
- Moderna's (MRNA) stock rose 1.31% after early testing showed that its mRNA mpox vaccine surpasses licensed competitors in alleviating symptoms and potentially reducing transmission, indicating its potential to expand beyond the Covid-19 market. Additionally, Nichole Wischoff has successfully raised $50 million for Wischoff Ventures to invest in over 30 startups, primarily in fintech, logistics, and manufacturing.
|
| 2024-09-04 | -0.62 % |
- Moderna (MRNA) stock fell by 0.62% amidst increased competition from Novavax's newly authorized COVID vaccine, which adds options for consumers alongside Moderna's own updated mRNA vaccines, reflecting the ongoing adaptation of the market in response to evolving COVID treatment strategies.
- Moderna (MRNA) stock recently declined by 0.62%, partially due to the Chief Legal Officer's stock sale related to tax obligations and ongoing concerns about the company's significant revenue decline, executive transactions, and cautious analyst outlooks on future sales and profitability.
- Moderna (MRNA) stock declined by 0.62% due to ongoing class action lawsuits alleging that the company made materially false and misleading statements about the effectiveness and commercial prospects of its mRNA-1345 product.
- Moderna's (MRNA) stock fell by 0.62% primarily due to concerns about low demand for COVID-19 vaccines, as pediatricians across the U.S. are scaling back orders in anticipation of parents' waning interest following a recent trend of underwhelming vaccination rates among eligible children.
- Moderna (MRNA) stock fell by 0.62% due to concerns over the company's financial performance and ongoing losses, suggesting a need for operational improvements to stabilize its profitability.
- Moderna (MRNA) stock has declined by 0.62% following the FDA's authorization of a new COVID-19 vaccine from Novavax, providing an alternative to its and Pfizer's vaccines, which may lead to reduced demand for Moderna's products.
- Moderna (MRNA) stock declined by 0.62% likely due to market reactions to developments in the COVID-19 vaccine landscape, including updated vaccine approvals and increased competition from other companies like Pfizer and Sunshine Biopharma, which are also advancing their COVID-19 treatments.
|
| 2024-09-03 | -5.76 % |
|
| 2024-08-30 | -0.24 % |
|
| 2024-08-14 | -0.78 % |
|
| 2024-08-12 | -4.29 % |
|
| 2024-08-08 | +3.4 % |
- Moderna (MRNA) stock rose by 3.4% due to positive developments in its collaborative research partnerships, particularly the progress and promising data from clinical trials related to its PROBODY therapeutic platform with CytomX Therapeutics.
- The article discusses the recent 3.4% increase in Moderna (MRNA) stock, attributing this rise to a positive outlook sparked by Needham's upgrade of Personalis, Inc. (PSNL), as well as Personalis' strong second-quarter results and upward revenue guidance, which bolster overall investor sentiment within the biotechnology sector.
- Moderna (MRNA) stock rose 3.4% likely due to positive developments at Personalis Inc., including a significant revenue increase and raised full-year guidance, which reflects investor confidence in strategic partnerships, including those with Moderna.
- Moderna (MRNA) stock increased by 3.4% likely due to positive developments and collaborations in the personalized cancer vaccine sector, particularly its partnership with Personalis, which has shown strong growth and promising advancements in its technology and services.
|
| 2024-08-06 | -1.73 % |
|
| 2024-08-05 | -3.27 % |
|
| 2024-08-02 | -8.06 % |
- The article discusses the advancements in the biotechnology market, specifically highlighting Moderna's ongoing development of mRNA vaccines funded by federal resources, amidst an overall decline in biotechnology venture capital funding and mixed investment opportunities.
Moderna's (MRNA) stock may have gone down by 8.06% due to a broader decline in biotech funding and market challenges, as reported by the EY Biotechnology Report 2024 which indicates that only companies with strong clinical data or market-ready assets are attracting significant investments, leading to investor caution.
- Moderna (MRNA) stock fell sharply by 8.06% amid a broader market decline triggered by disappointing job growth data, which heightened recession fears and led to increased volatility across major indexes.
The decline in Moderna's stock was part of a larger market selloff following a report that indicated the U.S. economy added fewer jobs than expected, raising concerns about a potential recession.
- Moderna (MRNA) stock fell 8.06% following the significant insider sale by director Noubar Afeyan, which may signal a lack of confidence amid the company's recent financial losses, declining vaccine sales, and lowered sales forecasts, despite some positive developments in other areas.
|
| 2024-08-01 | -21.01 % |
- Moderna (MRNA) stock experienced a significant decline of 21% due to disappointing disclosures about setbacks in its post-pandemic portfolio, which left investors questioning the company's future prospects as broader market concerns about a slowing economy intensified.
- Moderna (MRNA) stock fell 21% due to the company lowering its full-year sales forecast amidst disappointing international revenue expectations, despite reporting better-than-expected quarterly results.
- Moderna (MRNA) stock fell by 21.01% due to a significant 30% decline in Q2 sales, resulting in the company dropping below its 200-day moving average.
- Moderna (MRNA) stock fell by 21.01% due to concerns about the company's declining revenue and future growth prospects, particularly following difficulties in vaccine sales and market competition.
- Moderna (MRNA) stock fell by 21.01% amid a turbulent earnings season and macroeconomic uncertainties, including disappointing factory data and mixed signals from other major companies, as investors reacted negatively to the company's latest earnings report.
- Moderna (MRNA) stock fell by 21.2% after the company revised its full-year sales outlook down to $3 billion to $3.5 billion, citing low European Union sales, deferred international revenue, and increased competition in the respiratory vaccine market, despite beating second-quarter sales expectations.
- Moderna (MRNA) stock fell by 21.01% following Jefferies' revision of its price target from $180 to $120 and concerns over a projected $500 million to $1 billion reduction in 2024 revenue due to lower pricing of COVID-19 vaccines, deferrals in advanced purchase agreements, and modest expectations for its RSV vaccine.
- Moderna's stock fell by over 21% following the company's disappointing disclosures about setbacks in its COVID vaccine market in Europe, challenges in the competitive landscape for its new RSV vaccine, and a cut in its sales expectations for the year.
The primary reasons for the decline in Moderna's stock include its struggles to penetrate the COVID vaccine market in Europe, disappointing sales from its RSV vaccine launch due to stiff competition, a significant reduction in its projected sales outlook for 2024, and ongoing net losses that raise doubts about its profitability.
- Moderna (MRNA) stock fell by 18% due to a reduction in its full-year revenue guidance attributed to low sales in Europe and increased competition in the U.S. vaccine market.
|
| 2024-07-31 | +0.32 % |
|
| 2024-07-25 | +1.87 % |
|
| 2024-07-24 | -2.52 % |
|
| 2024-07-16 | +3.01 % |
|
| 2024-07-12 | -1.11 % |
|
| 2024-07-09 | -0.33 % |
|
| 2024-07-08 | -1.58 % |
|
| 2024-06-28 | -2.01 % |
|
| 2024-06-26 | -11.01 % |
|
| 2024-06-24 | +2.7 % |
|
| 2024-06-20 | +0.85 % |
|
| 2024-06-10 | -1.6 % |
- The article discusses Moderna Inc. preparing for the post-Covid era and mentions that last night Moderna (MRNA) stock was down by 1.6%, possibly due to factors such as market fluctuations, economic conditions, or profit-taking by investors.
- Summary: Moderna's combination vaccine for COVID-19 and influenza showed a stronger immune response in adults aged 50 and over, as per a late-stage trial, with plans for a potential launch in 2025 or 2026.
Reason for Moderna (MRNA) stock decline: The stock might have gone down due to factors like overall market conditions, profit-taking by investors, or reactions to the latest results or announcements from the company regarding the trial of the combination vaccine.
- Moderna's stock went down by 1.6% last night despite the company announcing that its Covid/flu vaccine outperformed competitors like GSK and Sanofi, as well as its own Spikevax shot.
- Summary: Moderna's stock, represented by the ticker symbol MRNA, was down by 1.6% last night as the company, led by CEO Stéphane Bancel, prepares for the post-Covid era, aiming to restore confidence in the vaccines sector.
Reason for stock decline: The decline in Moderna's stock may be attributed to various factors such as overall market conditions, investor sentiment, news related to the company's vaccine development progress, or general economic outlook.
- The article highlights five companies with high profitability and low debt, including Graco Inc., A.O. Smith Corp., Mueller Industries Inc., Warrior Met Coal Inc., and Axcelis Technologies Inc., offering investment suggestions. Moderna Inc. (MRNA) stock went down by -1.6% likely due to various market factors affecting the biotechnology sector, such as regulatory news, vaccine distribution concerns, or general market volatility.
|
| 2024-06-05 | +6.54 % |
|
| 2024-05-31 | -5.9 % |
|
| 2024-05-29 | -3.45 % |
|
| 2024-05-21 | +1.9 % |
|
| 2024-05-20 | +6.1 % |
|
| 2024-05-15 | +0.58 % |
|
| 2024-05-14 | +2.11 % |
|
| 2024-05-13 | +7.13 % |
|
| 2024-05-10 | -4.39 % |
- Summary: Moderna (MRNA) stock took a hit as the FDA delayed the approval decision on its RSV vaccine, citing administrative constraints, which pushed back the potential approval by two weeks but did not indicate any issues related to vaccine effectiveness, safety, or quality.
Reason for Moderna (MRNA) stock going down: The delay in the approval decision on Moderna's RSV vaccine by the FDA, caused by administrative constraints, led to a 4.39% drop in the stock price.
- Moderna (MRNA) stock declined last night by -4.39% due to a delay in the FDA's review of their new shot to treat respiratory syncytial virus (RSV), called mRNA-1345, which was expected to be approved earlier but is now anticipated to be reviewed at the CDC's Advisory Committee on Immunization Practices meeting at the end of June.
- Novavax (NVAX) stock nearly doubled after a $1.2 billion investment deal with Sanofi (SNY) for its COVID-19 vaccine, marking a turning point for the struggling biotech company and overshadowing Novavax's poor first quarter earnings; the stock of Moderna (MRNA) went down due to Novavax's significant cash boost and future growth prospects after a challenging period of manufacturing issues and missed pandemic opportunities.
- Moderna (MRNA) stock went down by -4.39% after the FDA informed the vaccine maker that the review of its RSV shot would be delayed, causing a setback in the expected approval timeline.
|
| 2024-05-09 | +0.66 % |
|
| 2024-05-06 | -2.3 % |
- The article discusses a range of financial news including the recent -2.3% drop in Moderna (MRNA) stock, attributed to various factors such as the continuation of earnings reports and market conditions indicating potentially increased stress on consumers amid the Fed's key interest rate remaining high.
- The article discusses Elis, a global leader in circular work services, and its positive Q1 2024 revenue growth, highlighting increased revenue and successful commercial initiatives. However, it also mentions that Moderna (MRNA) stock went down by -2.3% last night, possibly due to various factors impacting stock prices such as market sentiment, global economic conditions, news, or specific developments related to the company itself.
- The Moderna (MRNA) stock was down by -2.3% last night, as the article discusses various financial news and stock movements in the market, indicating that despite recent positive news around the company, such as potential boost from Bitcoin acceptance, there remain major threats to its business that may have contributed to the stock decline.
|
| 2024-05-03 | -0.47 % |
- The article discusses Moderna, Inc. preparing for the post-Covid era with their CEO, Stéphane Bancel, focusing on restoring confidence in the vaccines sector; however, the Moderna (MRNA) stock was reported to have been down by -0.47% last night, possibly due to various factors affecting the market sentiment, such as broader market conditions, news related to the company, or profit-taking by investors.
- The article highlights that Moderna (MRNA) stock was up almost 13% due to encouraging quarterly results, but then declined by -0.47% for unknown reasons.
- Moderna's (MRNA) stock went down by -0.47% due to uncertainties in the pharmaceutical industry, including Novo Nordisk facing scrutiny for patent issues and Johnson & Johnson settling lawsuits related to its products causing ovarian cancer.
|
| 2024-05-02 | +12.68 % |
- The article discusses Amgen's positive results and advancements in obesity treatments, leading to a surge in Amgen stock by 13.2%, which contributed to positive sentiment in the overall market, potentially influencing Moderna's stock to rise by 12.68% as well.
- Moderna (MRNA) stock surged 12.68% last night as the company reported a smaller-than-expected loss in EPS, beat sales estimates due to reduced COVID-19 vaccine sales, and successfully managed expenses, signaling cost-saving efforts amid declining vaccine demand, aligning with its planned trial schedules for other programs, as CEO Stéphane Bancel noted on Bloomberg Television, coupled with the company reiterating its 2024 sales expectations of around $4 billion and expecting growth in its respiratory franchise, following the termination of certain research programs.
- The article discusses how U.S. stock index futures rose, including Moderna (MRNA) stock, which was up by 12.68% the previous night, presumably due to market optimism following comments from Federal Reserve Chairman Jerome Powell and ahead of earnings reports from tech giant Apple.
- The article discusses how Moderna (MRNA) stock rose by over 12% after the company posted a narrower-than-expected loss for the first quarter, attributed to cost-cutting efforts and its Covid vaccine sales exceeding estimates. The stock likely went up due to positive financial results and strong vaccine sales performance.
- Moderna (MRNA) stock surged by 12.68%, as the company reported better-than-expected first-quarter results and hinted at launching a new product in the U.S., driving investor confidence and optimism in the stock.
|
| 2024-05-01 | +1.04 % |
|
| 2024-04-30 | -1.17 % |
- The article criticizes Ursula von der Leyen, the President of the European Commission, for lack of transparency in vaccine contracts, mentioning Pfizer, AstraZeneca, and Moderna, ultimately impacting Moderna (MRNA) stock negatively as investors may have concerns over the lack of accountability and transparency in these deals.
- Moderna (MRNA) stock was down by -1.17% last night; the overall market faced a downturn trend in April despite some recent rallies, with Moderna's stock likely going down due to overall market sentiment, including worries about interest rate hikes and company-specific expectations not being met.
- The article discusses a phase 3 trial of an mRNA-based seasonal influenza vaccine candidate by Moderna, Inc., indicating positive results; however, Moderna (MRNA) stock went down by -1.17% due to market factors.
|
| 2024-04-29 | +3.38 % |
|
| 2024-04-26 | +1.69 % |
- The article discusses Moderna, Inc. (NASDAQ: MRNA) director Noubar Afeyan selling 15,000 shares of Moderna stock, worth over $1.6 million, through a pre-arranged trading plan, yet still maintaining a substantial stake in the company. Moderna's stock has been on the rise, potentially due to recovering investor confidence, specific market conditions, and the company's cash position compared to its debt, along with management actively buying back shares to consolidate value for shareholders.
- The article discusses J.W. Cole Advisors Inc. increasing its stake in Moderna, Inc. (MRNA) and other hedge funds making changes to their positions in MRNA, ultimately leading to a 1.69% increase in Moderna's stock price. The stock likely went up due to increased institutional investment and positive ratings from equities analysts following Moderna's quarterly earnings report, which showed earnings exceeding expectations and revenue growth.
|
| 2024-04-24 | +0.89 % |
|
| 2024-04-23 | +3.28 % |
|
| 2024-04-22 | +3.01 % |
|
| 2024-04-19 | -0.58 % |
- Moderna (MRNA) stock went down last night as a result of Director Noubar Afeyan selling a substantial amount of company stock, totaling $1,550,703, in a series of transactions reported on April 17, 2024.
- The article discusses how Chinese vaccine developers of mRNA shots faced setbacks due to low demand, lack of revenue, and challenges in manufacturing plants, contrasting with Moderna, which plans to launch multiple mRNA medicines in China. Moderna's stock could have gone down due to increased competition and concerns about its dominance in the mRNA market.
- Summary: Blackstone Group Inc. (BX) reports strong Q1 2024 financial results, showcasing robust performance with strategic investments and an optimistic outlook for future growth and opportunities.
Reason for Moderna (MRNA) stock going down: The article primarily focuses on Blackstone Group Inc. and its financial performance in the first quarter of 2024, so it does not provide specific information on why Moderna's stock may have decreased.
|
| 2024-04-18 | -1.39 % |
|
| 2024-04-17 | -0.34 % |
|
| 2024-04-16 | -0.07 % |
- Mutual of America Capital Management LLC reduced its position in Moderna, Inc. (NASDAQ:MRNA) stock by 4.2%, leading to a decrease in the stock price last night by -0.07%; the stock decline could be attributed to movements by institutional investors and company insiders, as well as analyst ratings and the company's financial performance outlook.
- The article discusses Moderna's upcoming Annual Meeting for shareholders to vote on various proposals, including electing directors and approving executive compensation, with a proxy summary highlighting the company's mission, performance, and strategic priorities. The -0.07% drop in Moderna (MRNA) stock last night could be due to various factors such as market volatility, profit-taking by investors, changes in industry trends, or general economic conditions impacting the biotech sector.
- The article discusses the interplay between U.S. government agencies like the Department of Defense and pharmaceutical companies such as Pfizer and Moderna, highlighting how personnel move between these sectors and how this affects decision-making and financial gain. Moderna's stock went down likely due to the negative sentiments around the intertwined relationships between government agencies, corporations, and the pharmaceutical industry, as discussed in the article.
|
| 2024-04-15 | -1.22 % |
- The article discusses how Novavax's failure to market its traditional protein-based COVID-19 vaccine to individuals hesitant to take mRNA vaccines led to a decline in sales and stock price, impacting Novavax, Moderna, and Pfizer, contributing to the overall downward trend in the vaccine producer stocks.
- The article discusses the stock movements of Microsoft (NASDAQ: MSFT) and mentions various institutional investors buying and selling shares of the company, contributing to its overall activity in the stock market. Moderna (NASDAQ: MRNA) stock went down likely due to the overall market conditions, investor sentiment, or specific news related to the company.
- Summary: Viatris Inc. appoints Corinne Le Goff as Chief Commercial Officer, boosting investor interest in the company, with a focus on their financial health and market performance, while Moderna (MRNA) stock fell by -1.22%, impacted by reasons outside of this article.
Reason for Moderna (MRNA) stock going down: The article does not directly state the reason for Moderna (MRNA) stock going down, as it primarily focuses on Viatris Inc. and Corinne Le Goff's appointment as its Chief Commercial Officer, highlighting financial information and market performance relevant to Viatris.
- The article announces the appointment of Corinne Le Goff as the Chief Commercial Officer at Viatris Inc., a global healthcare company, following her previous role as the Chief Commercial Officer at Moderna. Moderna's stock went down likely due to factors such as market trends, investor sentiment, or specific news related to the company itself.
|
| 2024-04-12 | -1.75 % |
- The article reports that Moderna (MRNA) stock went down by -1.75% as the company announced pausing plans for a vaccine manufacturing facility in Kenya due to decreased demand for COVID-19 vaccines post-pandemic, affecting the company's strategic planning and financial outlook.
- Moderna's stock went down by -1.75% as the company announced a pause in building an mRNA manufacturing facility in Kenya due to declining demand for COVID-19 vaccines in Africa, resulting in losses and write-downs of more than $1 billion.
- The Moderna (MRNA) stock rose after positive results for an experimental cancer vaccine, but went down due to pausing plans to build a manufacturing facility in Kenya because of low demand for mRNA vaccines in Africa.
- Summary: Noubar Afeyan, a director at Moderna, Inc., sold over $1.6 million worth of company stock in multiple transactions, utilizing a pre-arranged trading plan; this insider selling activity could be part of Afeyan's regular financial planning strategy and does not necessarily indicate a change in the company's future prospects, although it may have contributed to the -1.75% decline in Moderna (MRNA) stock.
Reason for Moderna (MRNA) stock decline: The selling activity of company stock by Noubar Afeyan, a company director, contributed to the decline in Moderna (MRNA) stock, as insider selling can sometimes lead investors to reassess their confidence in the company and its future prospects.
|
| 2024-04-11 | -0.12 % |
|
| 2024-04-10 | -4 % |
|
| 2024-04-09 | +6.19 % |
|
| 2024-04-08 | +2.15 % |
- The article discusses a study on mRNA-4157 (V940) combined with pembrolizumab in patients with HPV-negative head and neck squamous cell carcinoma, showing preliminary positive clinical responses and immune activation, potentially leading to the increase in Moderna (MRNA) stock.
- The article discusses CytomX's progress and advancements in cancer research, particularly focusing on their PROBODY therapeutic platform that aims to deliver safer and more effective treatments for cancer patients through innovative biologic therapies. The increase in Moderna's stock (MRNA) could be due to its partnership with CytomX and the promising developments in the field of oncology, such as the potential of masked therapeutics like the ones developed by CytomX to revolutionize cancer treatment.
- Summary: Moderna (MRNA) stock rose by 2.15% after Director Noubar Afeyan sold 15,000 shares, indicating positive investor sentiment possibly due to the company's quarterly earnings exceeding expectations and developments in mRNA therapeutics and vaccines.
Reason for stock increase: The stock went up possibly due to positive investor sentiment after Moderna reported earnings per share exceeding expectations, along with developments in mRNA therapeutics and vaccines for various diseases.
- The article discusses positive preliminary Phase I results for Clover Biopharmaceuticals' bivalent RSV vaccine candidate, leading to a 2.15% increase in Moderna stock last night; the increase in Moderna stock could be attributed to the promising immunogenicity and safety data of Clover's RSV vaccine candidate, SCB-1019, as it generated significant neutralizing antibody responses against RSV-A and RSV-B, demonstrating potential efficacy and safety outcomes.
|
| 2024-04-05 | +0.6 % |
|
| 2024-04-04 | +1.05 % |
- The article discusses how Moderna (MRNA) stock closed lower on Wednesday due to news surrounding Arbutus Biopharma impacting investor sentiment, but went up by 1.05% last night; however, the reason behind this increase is not mentioned in the given summary.
- The article discusses Arbutus Biopharma Corporation's lawsuit against Moderna, Inc. and a Moderna affiliate regarding patent infringement in the manufacture and sale of Moderna's COVID-19 vaccine. Moderna's stock went up 1.05%, likely due to positive developments in the lawsuit and continued efforts to protect its intellectual property related to its successful COVID-19 vaccine, MRNA-1273.
- The article discusses various economic indicators such as the US Federal Reserve's monetary policy stance, tightening labor market, Spotify's subscription price hike, Turkish inflation data, and news related to Moderna (MRNA) stock value declining due to a patent infringement ruling. Moderna (MRNA) stock went up last night by 1.05%, likely due to overall positive market sentiment and investor confidence.
- The article discusses the potential threat of a new strain of avian influenza, H5N1, highlighting efforts by companies like Moderna to develop vaccines against it, which has contributed to a 1.05% increase in Moderna (MRNA) stock.
|
| 2024-04-03 | -2.32 % |
|
| 2024-03-28 | -3.64 % |
|
| 2024-03-27 | +2.96 % |
- Summary: Moderna (MRNA) stock was up by 2.96% following news of the biotech firm securing funding to develop mRNA flu vaccines.
Reason for Moderna (MRNA) stock increase: Moderna stock went up after the company announced a $750 million agreement with Blackstone's life science investment platform for funding to develop its mRNA flu vaccines.
- Summary: Blackstone Life Sciences has entered into a collaboration agreement with Moderna (MRNA), investing up to $750 million to support Moderna's influenza program, aiming to further advance mRNA vaccine technology.
Reason for Moderna (MRNA) stock going up: Moderna's partnership with Blackstone Life Sciences for funding its influenza program, indicating continued progress and development in its mRNA pipeline, likely led to increased investor interest and contributed to the stock's 2.96% increase.
- Moderna's stock rose by 2.96% following the announcement of late-stage clinical trials for a range of vaccines targeting different viruses using mRNA technology, apart from COVID-19, like Norovirus, Epstein Barr virus, Varicella-Zoster virus, and RSV, which are showing promising results, indicating potential future growth and market opportunities for the company.
- The article discusses how Blackstone has agreed to fund up to $750 million of Moderna's research for an influenza vaccine, assisting Moderna in developing new vaccines and reducing research costs, which likely contributed to Moderna (MRNA) stock rising by 2.96% due to the positive news and financial support from Blackstone.
- Moderna (MRNA) stock went up by 2.96% last night as the biotech firm made significant announcements at its "Vaccines Day" event, including new funding from Blackstone Life Sciences and positive clinical data from several vaccine trials, leading to investor optimism about the company's vaccine pipeline and potential future successes.
|
| 2024-03-26 | -2.69 % |
- The article highlights that Moderna (MRNA) stock went down by -2.69% last night, even though Super Micro Computer (SMCI), Micron Technology (MU), Constellation Energy (CEG), and Dexcom (DXCM) were top gainers on the S&P 500 index; the reason for the decline in Moderna's stock could be various factors such as market sentiment, news releases, economic indicators, or company-specific developments.
- The article discusses Moderna, Inc. and mentions that its stock was down by -2.69% last night, possibly due to market factors influencing the pharmaceutical industry rather than any specific news related to Moderna itself.
- The article discusses ARK ETFs' recent moves in the market, which included buying shares of Tesla and Roblox while selling off holdings in companies like Coinbase and DraftKings, and investing in Moderna. Moderna (MRNA) stock went down last night (March 25, 2024) by -2.69% as a part of market fluctuations and overall strategic adjustments made by ARK ETFs in their investment portfolio.
- The article provides an update on Moderna's new COVID-19 vaccine, mRNA-1283, which showed increased effectiveness and promising features such as longer shelf life and a pre-filled syringe design. Despite these advancements, Moderna's stock experienced a 2.69% decline, possibly due to concerns around the market's response to the company's profit growth, decreasing use of its current product, and the slow adoption of the updated COVID-19 vaccine in the U.S.
|
| 2024-03-25 | +4.7 % |
|
| 2024-03-22 | +1.29 % |
- Moderna (MRNA) stock was 1.29% up last night, despite falling 3.7% during mid-day trading on Wednesday, with a variety of research firms offering mixed ratings on the stock; the stock rise may be attributed to positive earnings results, including beating estimates for earnings per share and revenue, as well as the company's development and commercialization of mRNA therapeutics and vaccines for various diseases.
- The article discusses Moderna, Inc. (NASDAQ:MRNA) director Noubar Afeyan selling a significant amount of company stock, worth $1,535,820, which was executed through a pre-arranged trading plan; however, the stock price of Moderna (MRNA) increased by 1.29% last night due to various factors like insider sales not always indicating a change in company fundamentals and investors closely monitoring the company's financial health and stock performance in the post-pandemic market.
- The article mentions that Moderna (MRNA) stock was up by 1.29% last night. The stock likely went up due to positive investor sentiment, potentially driven by news related to the company's COVID-19 vaccine or other developments.
|
| 2024-03-21 | +0.98 % |
|
| 2024-03-20 | -1.93 % |
|
| 2024-03-19 | +0.82 % |
|
| 2024-03-18 | +0.39 % |
|
